Why did FDA refuse Moderna's flu shot?

Question

Hans Steiner · Accepted Answer

U.S. regulator halted review of Moderna’s mRNA influenza application

The Food and Drug Administration declined to accept Moderna’s application seeking approval for an mRNA-based seasonal influenza vaccine, creating an unexpected roadblock for the company and broader interest in mRNA approaches to flu. U.S. regulators flagged how Moderna designed its pivotal trial: the company compared its candidate against a flu vaccine that the FDA judged was not the best standard of care for the population studied. That trial choice was central to the agency’s decision not to move forward with a formal review.

The refusal was unusual enough to draw public debate. Senior agency actions also included internal controversy: reporting indicates a senior official overruled the recommendations of some agency reviewers in taking the refusal. Moderna has said it will request a meeting with the FDA to discuss the decision and its next steps.

What this means now

For Moderna: the company must engage with regulators to clarify trial comparisons and whether new data or analyses can address the agency’s concerns. Moderna has not been granted an acceptance of its application, so licensing cannot proceed until the matter is resolved.
For other vaccine makers: the move signals that trial design—particularly the choice of comparator vaccine—will be scrutinized closely for any future mRNA or updated flu shots.
For public health and clinicians: the timing of additional vaccine options may be delayed, potentially affecting seasonal vaccine supply and planning.

Unknowns and outstanding questions

It’s still unclear whether the FDA’s decision is final or can be reversed quickly after a meeting, and exactly what additional evidence the agency would require to accept a filing. The longer-term regulatory precedent—how strictly the agency will police comparator choices in vaccine trials—remains to be seen.